I-Mab (NASDAQ:NBP) Stock Rating Lowered by Wall Street Zen

I-Mab (NASDAQ:NBP) was downgraded by Wall Street Zen from a “sell” rating to a “strong sell” rating in a report issued on Monday, Wall Street Zen reports.

A number of other research analysts also recently issued reports on NBP. Weiss Ratings restated a “sell (d-)” rating on shares of I-Mab in a research report on Thursday, August 27th. HC Wainwright restated a “buy” rating and set a $9.00 price target on shares of I-Mab in a report on Thursday, August 20th. One analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $9.00.

I-Mab Stock Performance

Shares of NASDAQ:NBP opened at $1.78 on Monday. I-Mab has a 52 week low of $1.46 and a 52 week high of $6.79. The firm has a market cap of $205.86 million, a PE ratio of -4.94 and a beta of 1.50. The firm’s fifty day moving average is $1.83 and its 200-day moving average is $2.16.

I-Mab (NASDAQ:NBP) last posted its quarterly earnings data on Thursday, August 20th. The company reported ($0.16) earnings per share for the quarter. Sell-side analysts forecast that I-Mab will post -0.3 EPS for the current year.

Institutional Trading of I-Mab

A hedge fund recently bought a new stake in I-Mab stock. Brooklyn Investment Group purchased a new stake in shares of I-Mab (NASDAQ:NBP) in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund purchased 12,715 shares of the company’s stock, valued at approximately $51,000. 38.38% of the stock is owned by institutional investors.

I-Mab Company Profile

I-Mab is a clinical-stage biotechnology company focused on the discovery, development and commercialization of biologic therapies for oncology and immunology indications. The company concentrates on advancing antibody-based therapeutics and other protein biologics intended to modulate the immune system to treat cancer and autoimmune or inflammatory diseases. Its development activities span preclinical research through late-stage clinical trials, with an emphasis on creating targeted, differentiated molecules designed to address unmet medical needs.

Headquartered in China with global development activities, I-Mab operates research and development facilities and engages with clinical investigators and regulatory authorities across multiple geographies to support global clinical programs.